ZLAB Zai Lab Ltd
Pharmaceutical Preparations · Nasdaq · SEC CIK 1704292 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.0%
TTM net income YoY4.1%
TTM EPS YoY5.3%
Revenue 3-yr CAGR18.8%
Net income 3-yr CAGR—
Margins
Gross margin54.7%
Operating margin-63.0%
Net margin-44.9%
FCF margin-37.0%
EBITDA margin-60.1%
Returns
ROE-30.0%
ROA-18.2%
ROIC (approx.)-779.4%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets45.0%
Debt / equity0.00x
Current ratio2.04x
Interest coverage-45.16x
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $108.21M | $106.31M | $99.61M | $127.60M | $116.09M | $109.98M | $106.49M | $109.07M |
| Cost of revenue | $51.30M | $48.16M | $38.31M | $62.30M | $46.76M | $43.00M | $38.45M | $41.78M |
| Gross profit | $56.90M | $58.15M | $61.30M | $65.30M | $69.33M | $66.97M | $68.03M | $67.29M |
| R&D expense | $49.81M | $61.77M | $65.59M | $61.63M | $47.93M | $50.61M | $60.73M | $52.25M |
| SG&A expense | $70.07M | $72.87M | $65.07M | $73.04M | $70.11M | $71.04M | $63.42M | $82.62M |
| Operating income | -$62.98M | -$76.49M | -$69.39M | -$69.41M | -$48.82M | -$54.90M | -$56.31M | -$67.89M |
| Interest expense | $1.58M | $1.59M | $1.64M | $1.36M | $1.40M | $1.26M | $1.19M | $904,000 |
| Pretax income | -$48.01M | -$51.85M | -$49.58M | -$53.34M | -$35.96M | -$40.73M | -$48.44M | -$81.68M |
| Income tax | -$1.87M | -$1.02M | $1.44M | -$2.93M | $0 | $0 | $0 | $0 |
| Net income | -$46.14M | -$50.83M | -$51.02M | -$50.41M | -$35.96M | -$40.73M | -$48.44M | -$81.68M |
| EBITDA | -$60.68M | -$74.09M | -$65.44M | -$65.49M | -$46.42M | -$52.59M | -$52.85M | -$64.86M |
| EPS (basic) | -0.04 | -0.05 | -0.05 | — | -0.03 | -0.04 | -0.04 | — |
| EPS (diluted) | -0.04 | -0.05 | -0.05 | — | -0.03 | -0.04 | -0.04 | — |
| Weighted avg. shares (diluted) | 1.12B | 1.12B | 1.11B | — | 1.10B | 1.09B | 1.08B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $549.66M | $607.52M | $651.32M | $679.57M | $717.15M | $732.16M | $757.26M | $449.67M |
| Short-term investments | $10.00M | $10.00M | $10.00M | $10.00M | $0 | $0 | $0 | $330.00M |
| Receivables | $65.30M | $69.59M | $54.07M | $106.12M | $85.38M | $88.50M | $76.56M | $85.18M |
| Inventory | $85.29M | $90.89M | $85.96M | $74.75M | $67.14M | $61.70M | $53.05M | $39.88M |
| Current assets | $864.40M | $914.04M | $944.73M | $1.02B | $1.03B | $1.03B | $1.04B | $1.05B |
| PP&E, net | $46.08M | $46.43M | $47.07M | $47.39M | $48.87M | $50.16M | $49.65M | $47.96M |
| Intangibles | $85.30M | $85.77M | $75.76M | $76.14M | $55.28M | $56.52M | $56.20M | $56.03M |
| Total assets | $1.02B | $1.07B | $1.10B | $1.17B | $1.16B | $1.16B | $1.17B | $1.19B |
| Current liabilities | $424.25M | $428.58M | $392.98M | $416.17M | $359.77M | $331.50M | $319.81M | $299.38M |
| Short-term debt | $252.37M | $238.10M | $213.82M | $204.53M | $203.03M | $174.51M | $173.41M | $131.71M |
| Total liabilities | $460.62M | $467.76M | $433.76M | $456.88M | $399.00M | $372.37M | $362.58M | $344.86M |
| Shareholders' equity | $563.28M | $607.04M | $661.98M | $715.50M | $759.95M | $791.74M | $810.75M | $840.90M |
| Shares outstanding | 1.12B | 1.12B | 1.11B | 1.11B | 1.11B | 1.10B | 1.08B | 1.08B |
| Cash flow statement | ||||||||
| Operating cash flow | -$57.87M | -$63.41M | -$11.91M | -$26.02M | -$32.04M | -$31.02M | -$61.70M | -$55.77M |
| Capital expenditure | $947,000 | $1.31M | $1.20M | $677,000 | $3.00M | $2.88M | $1.53M | $2.60M |
| Free cash flow | -$58.81M | -$64.72M | -$13.11M | -$26.70M | -$35.05M | -$33.91M | -$63.23M | -$58.37M |
| Investing cash flow | -$12.68M | -$1.42M | -$22.29M | -$11.30M | -$4.05M | -$2.92M | $326.13M | -$347.75M |
| Financing cash flow | $14.05M | $18.70M | $5.57M | -$430,000 | $20.79M | $8.85M | $43.14M | $237.81M |
| Depreciation & amortization | $2.30M | $2.40M | $3.94M | $3.92M | $2.40M | $2.30M | $3.46M | $3.03M |
| Stock-based compensation | $11.34M | $12.13M | $13.52M | $15.90M | $16.92M | $16.97M | $15.80M | $17.24M |
Free plan shows the latest 8 periods; Pro shows all 30 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.